About the Company

About Kowa Pharmaceuticals America, Inc.

In July of 2008, Kowa Company, Ltd., of Nagoya, Japan, acquired ProEthic Pharmaceuticals, Inc., and Kowa Pharmaceuticals America, Inc. (KPA) was born.

Kowa’s step into the U.S. pharmaceutical market represents a significant step towards its vision of creating a global pharmaceutical organization. KPA is a specialty pharmaceutical company focused primarily in the areas of cardiology, pain and migraine. The privately held company focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical products.

The first pharmaceutical product to be launched by the new company will be pitavastatin, a novel HMG CoA reductase inhibitor for the treatment of hyperlipidemia. Pitavastatin is sold in Japan, Korea and Thailand under the brand Livalo(R). Pitavastatin has recently completed Phase 3 clinical development in Europe and the United Sates

About Kowa Company, Ltd.

Since its establishment in 1894, Kowa has grown into a multinational Japanese company actively engaged in various manufacturing and trading activities in the fields of pharmaceutical, life science and information technology, textiles, machinery and various consumer products. During its long history, Kowa has consistently strived to meet the changing needs, and with its continuing entrepreneurial initiative, is determined to meet the needs of future generations. It is this commitment to consistency and initiative in an ever-changing world that Kowa vows to carry forward through each generation.

To visit Kowa Company, Ltd.’s website, please visit www.kowa.com.

About Kowa Research Institute, Inc.

Kowa Research Institute, Inc. (KRI) located in the RTP area of North Carolina is responsible for the clinical development of Kowa Company’s new drugs in the United States. Kowa Research Institute, Inc. is a division of Kowa Co., Ltd. Kowa Research Institute was established in 1997 in California and began operations at the current location in 2003.